Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Gilead Sciences (NQ: GILD)
62.98 USD  -0.22 (-0.35%)
Official Closing Price  /  Updated: 7:51 PM EST, Jan 17, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 13,457,600
Open 63.50
Bid (Size) 62.90 (1)
Ask (Size) 62.98 (4)
Prev. Close 63.20
Today's Range 62.57 - 63.50
52wk Range 60.89 - 70.50
Shares Outstanding 1,300,260,832
Dividend Yield 3.54%
Performance
YTD
-3.45%
-3.45%
1 Month
-4.11%
-4.11%
3 Month
-2.97%
-2.97%
6 Month
-3.17%
-3.17%
1 Year
-8.26%
-8.26%
Top News
More News
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Collaboration Brings Together Gilead's Commitment to Advancing Cell Therapy with Kyverna's Focus on Advanced T Cell Engineering Targeting Autoimmune Diseases Read More
from PR Newswire
Technological Advancements Expand Biopharmaceuticals' Production Capabilities
FinancialBuzz.com News Commentary Read More
from PR Newswire
More News
Read More
Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
from Business Wire News Releases
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
from GlobeNewswire News Releases
PJP's Underlying Holdings Could Mean 14% Gain Potential
category ETFs
from ETF Channel
Notable Monday Option Activity: AIMT, NKE, GILD
category Stocks
from Market News Video
IBB, GILD, VRTX, BIIB: Large Inflows Detected at ETF
category ETFs
from ETF Channel
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
category Trading Ideas , Analyst Ratings , VRTX , and 19 more.
from Benzinga
Market Briefing For Jan. 13, 2020
from Blogs - TalkMarkets
Better Buy: Biogen vs. Gilead Sciences
category IBB , GLPG , Market News , and 3 more.
from Motley Fool
REFILE-EXPLAINER-Making a new generation of 'guided-missile' cancer drugs work
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.